Key result
An ACEF score ≥ 1.22 was an independent predictor of 5-year all-cause mortality in invasively managed NSTE-ACS patients (HR 10.98).
Why the study?
Does the ACEF score predict 5-year mortality in invasively managed NSTE-ACS patients?
Observational (n=196)
No
Does the ACEF score predict 5-year mortality in invasively managed NSTE-ACS patients?
The ACEF score is a simple and effective tool for long-term risk stratification and predicting 5-year mortality in patients with NSTE-ACS managed invasively.
Answers are grounded in this paper and cite their sources.
May aid long-term risk stratification in NSTE-ACS; hypothesis-generating, requires prospective validation before practice change.
Long-term risk stratification in non-ST-elevation acute coronary syndrome (NSTE-ACS) by the ACEF score has not yet been assessed. The ACEF score (age/left ventricular ejection fraction +1 [if creatinine > 20 mg/l]) has been established in patients evaluated for coronary artery bypass surgery.
No takes yet. Share an insight, caveat, or question.
Boukerche et al. (2022) conducted an observational in Non-ST-elevation acute coronary syndrome (NSTE-ACS) (n=196). ACEF score ≥ 1.22 vs. ACEF score < 1.22 was evaluated on 5-year all-cause mortality (HR 10.98, 95% CI 4.34-27.80, p=< 10^-3). An ACEF score ≥ 1.22 was an independent predictor of 5-year all-cause mortality in invasively managed NSTE-ACS patients (HR 10.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: